ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2815

Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy

T. Martijn Kuijper1, J.J. Luime1, P.H.P. de Jong2, A. H. Gerards3, D. van Zeben4, I. Tchetverikov5, P.B.J. de Sonnaville6, M. van Krugten7, B. Grillet8, J.M.W. Hazes9 and A.E.a.M. Weel10,11, 1Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 3Rheumatology, Vlietland Hospital, Schiedam, Netherlands, 4Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5Albert Schweitzer Hospital, Dordrecht, Netherlands, 6Rheumatology, Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 7Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands, 8Rheumatology, ZorgSaam Hospital, Terneuzen, Netherlands, 9Rheumatology, Erasmus MC, Rotterdam, Netherlands, 10Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 11Rheumatology, MD, PhD, Rotterdam, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic agents, combination therapies, Disease Activity, functional status and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects V: Mortality and Other Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

To assess differences in frequency of biological therapy use and functional ability in early RA patients two years after starting induction therapy according to three different treatment regimens.

Methods:

Data were used from patients with recent-onset arthritis participating in a single-blinded clinical trial (Treatment in the Rotterdam Early Arthritis CoHort (tREACH))(1) in which three induction therapy strategies were compared: (A1) combination therapy (methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with glucocorticoids (GCs) intramuscularly; (A2) combination therapy with an oral GC tapering scheme and (B) MTX with oral GCs similar to B. As no difference in disease activity scores (DAS) was found between groups A1 and A2 at 3 and 12 months of follow-up(1), these groups were combined for this analysis (group A). Disease activity scores (original DAS) were assessed every 3 months. Functional ability was assessed using the Health assessment questionnaire (HAQ). Data were analysed using simple descriptive statistical techniques.

Results:

281 patients (91 men, 190 women; mean baseline DAS 3.3, median baseline HAQ 1.00) were initially randomized. Data on medication use at 2 years were available from 248 patients (88%), see figure 1. At 2 years, 24% of patients in group A versus 43% in group B were using a biological DMARD. Biological use and DAS over time are demonstrated in figure 2.

Equal mean DAS of 1.66 (95%CI 1.54-1.78) at 24 months was observed for the initial treatment groups at 24 months (group A: 1.58 (95%CI 1.43-1.73), group B: 1.80 (95%CI 1.58-2.02). DAS remission (DAS<1.6) was achieved by 53% of patients.

The median disability score (HAQ (min-max)) was 0.38 (0-2) for all patients but varied in the treatment groups: A. 0.25 (0-1.9) and B. 0.63 (0-2.1) (p=0.042).

 

Conclusion:

We observed lower use of biological therapy and better functional ability in induction triple therapy compared to induction monotherapy MTX with GC bridging at  2 years of follow-up in the treat-to-target tREACH study. No differences were found for disease activity scores.

1.    De Jong et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014 Jul;73(7):1331-9.


Disclosure:

T. M. Kuijper,
None;

J. J. Luime,
None;

P. H. P. de Jong,
None;

A. H. Gerards,
None;

D. van Zeben,
None;

I. Tchetverikov,
None;

P. B. J. de Sonnaville,
None;

M. van Krugten,
None;

B. Grillet,
None;

J. M. W. Hazes,
None;

A. E. A. M. Weel,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/better-functional-ability-with-less-biologicals-2-years-after-induction-with-combination-dmard-therapy-versus-methotrexate-monotherapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies